A series of cardiometabolic-related news items has been observed from Lilly, Viking Therapeutics, Merck, and FDA. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related new items has been observed from Pfizer, Novo Nordisk, Merck, Amgen, and Zonsen PepLib Biotech/Lilly. Below, FENIX provides highlights and insights for the respective news items.
On the second day of JPM 2026, FENIX has provided coverage of presentations by major CVRM companies, including Lilly, Novo Nordisk, Amgen, Viking Therapeutics, AstraZeneca, Merck, and Ionis Pharmaceuticals. Separately, one CVRM-related news item has been observed: The Obesity Association published new standards of care for obesity medications (view press release). Below, FENIX provides insights and highlights for the guidelines.
On the second day of JPM 2025, FENIX has provided coverage of presentations by major CVRM companies, including Lilly, AstraZeneca, Sanofi, Novartis, Bayer, Akero, Scholar Rock, Sandoz, Merck, Teladoc, and Viatris. Of note, JPM experienced webcast issues during the 9:45 AM PT time slot. Separately, one CVRM-related news item has been observed: Dario partnered with MediOrbis for GLP-1RA solution expansion (view press release).
A series of cardiometabolic-related news items have been observed from Pfizer, Merck, Fractyl Health, NewAmsterdam Pharma, and Imperial College London. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items have been observed from Syntis Bio, Akero Therapeutics, Merck, and Nanexa AB. Below, FENIX provides highlights and insights for the respective news items.
Four cardiometabolic-related news items have been observed from Viking Therapeutics, AstraZeneca, Sanofi, and Merck. Below, FENIX provides highlights and insights for the respective news items.
Five cardiometabolic-related news items have been observed from Novo Nordisk, NeuroBo, Merck, Roche, and Sanofi. Below, FENIX provides the highlights and insights for the respective news items.
Four cardiometabolic-related news items have been observed: FDA granted Fast Track Designation to Altimmune’s pemvidutide for the treatment of NASH (view press release); Diamyd announced results from a retrospective follow-up study of two prior trials, DiAPREV-IT and DiAPREV-IT2 (view press release); Viking (press release) and Merck (press release; slides) hosted their respective Q3 ’23 earnings call. Below, FENIX provides highlights and insights for the respective news items.
Four cardiometabolic-related news items have been observed: Novo Nordisk is reportedly having difficulties meeting Wegovy demand in Germany (view article); Abata Therapeutics disclosed its development candidate, ABA-201, to be a disease-modifying Treg cell therapy for T1DM (view press release); Bayer announced it will initiate three additional finerenone Ph3 studies as part of its HF MOONRAKER development program (view press release); and Merck initiated its oral PCSK9i (MK-0616) CVOT (view CT.gov record). Below, FENIX provides highlights and insights into the respective news items.